Alterity Therapeutics Limited - Sponsored ADR (ATHE)
(Delayed Data from NSDQ)
$5.40 USD
+0.19 (3.65%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $5.36 -0.04 (-0.74%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ATHE 5.40 +0.19(3.65%)
Will ATHE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATHE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ATHE
Alterity's (ATHE) ATH434 Gains U.S. FDA Fast Track Status for MSA
Appendix 4C -- Q4 FY25 Quarterly Cash Flow Report | ATHE Stock News
Alterity Therapeutics reports cash balance of A$40.66M as of June 30
12 Health Care Stocks Moving In Monday's Intraday Session
Alterity Therapeutics (ATHE) Reports Positive Trial Results for ATH434